GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective ...

Initial report of a randomized trial of post-prostatectomy prostate cancer radiotherapy using either fluciclovine (18F) or PSMA (68Ga) PET/CT for target dose-escalation. This is an ASCO Meeting ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Wolfgang P.

With a new treatment for prostate cancer in play, men with more aggressive forms of prostate cancer may have a more positive ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

Gozetotide binds to the cancer cells with prostate-specific membrane antigen (PSMA) on their surface, making them visible ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.

Telix Pharmaceuticals has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the ...

UK MHRA grants marketing authorization to Telix’s prostate cancer PET imaging agent, Illuccix: Melbourne, Australia Friday, February 14, 2025, 10:00 Hrs [IST] Telix, a commercia ...

PSMA-PET imaging [2] represents a major advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT [3] scan) as the standard of care after initial ...

[99mTc]Tc-iPSMA SPECT/CT as an alternative to PET imaging for decision making in prostate cancer patients. PREP registry: Key findings. Total (n=4135) Cohort 1 (n=255): BF within 3 months from RP and ...